<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04086940</url>
  </required_header>
  <id_info>
    <org_study_id>Ain Shams university 1</org_study_id>
    <nct_id>NCT04086940</nct_id>
  </id_info>
  <brief_title>Role of Intraoperative Beta Blocker for Morbid Obese Patients Undergoing Laparoscopic Bariatric Surgery</brief_title>
  <official_title>Lecturer of Anesthesia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ain Shams University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Using esmolol during anesthetic maintenance of laparoscopic bariatric surgery significantly
      decreases anesthetic, analgesic requirements, postoperative pain, PNV and postoperative
      hypoxia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Postoperative pain, nausea, vomiting (PNV) and hypoxia are common in relation to laparoscopic
      bariatric surgery. Sympatholytic drugs might decrease the need for intravenous or Inhalation
      anesthetics and opioids. In this study we wanted to analyze effects of esmolol on
      intraoperative anesthetic-analgesic requirements, postoperative analgesic requirements,
      postoperative pain, PNV and hypoxia.

      Methods: Sixty patients have been included. Propofol, fentanyl and rocuronium were used for
      induction. Study groups were as follows; group E Esmolol infusion was added to maintenance
      anesthetics (Sevoflurane and fentanyl), group N only Sevoflurane and fentanyl was used during
      maintenance. They have been monitored during the intraoperative period and postoperatively
      for 24 h for analgesic requirements and PNV. Visual analog scale (VAS) scores for pain was
      also been assessed.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2019</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">November 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>prospective randomized controlled study</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>intraoperative analgesic requirements</measure>
    <time_frame>6 months</time_frame>
    <description>amount of narcotics and anesthetics needed</description>
  </primary_outcome>
  <primary_outcome>
    <measure>postoperative analgesic requirements</measure>
    <time_frame>6 months</time_frame>
    <description>amount of narcotics needed</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Intraoperative Awareness</condition>
  <condition>Postoperative Pain</condition>
  <arm_group>
    <arm_group_label>esmolol(breviblock) group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in group E received a loading dose of esmolol(breviblock) 1 mg/kg in 50 ml isotonic saline over 30 minutes before induction of anesthesia, then followed by an infusion of esmolol 10 Âµg/kg/min until the end of the surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>non esmolol group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in group N received 50 ml of isotonic saline over 30 min, followed by an infusion of isotonic saline at same rate of group E till the end of the surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Esmolol</intervention_name>
    <description>preventive</description>
    <arm_group_label>esmolol(breviblock) group</arm_group_label>
    <arm_group_label>non esmolol group</arm_group_label>
    <other_name>normal saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  American Society of Anesthesiologists (ASA) I - II patients

          -  age between 18-59 years

          -  both genders

          -  body mass index (BMI) &gt; 45 kg/m2

        Exclusion Criteria:

          -  Patients with -hepatic

          -  renal

          -  cardiac

          -  respiratory diseases

          -  patients with a history of drug abuse or who were dependent on opioid drugs.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>59 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Ramymahrose</name>
      <address>
        <city>Cairo</city>
        <zip>02</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>September 5, 2019</study_first_submitted>
  <study_first_submitted_qc>September 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 12, 2019</study_first_posted>
  <last_update_submitted>November 21, 2019</last_update_submitted>
  <last_update_submitted_qc>November 21, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams University</investigator_affiliation>
    <investigator_full_name>RAMY AHMED</investigator_full_name>
    <investigator_title>lecturer of anesthesia at faculty of medicine ain shams university</investigator_title>
  </responsible_party>
  <keyword>role</keyword>
  <keyword>INTRAOPERATIVE</keyword>
  <keyword>beta blocker</keyword>
  <keyword>bariatric surgery</keyword>
  <keyword>morbid obese</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Intraoperative Awareness</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esmolol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>after publication</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

